Targeting Collagen Pathways as an HFpEF Therapeutic Strategy: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Alice Bonanni
,
Ramona Vinci
,
Alessia d’Aiello
,
Maria Chiara Grimaldi
,
Marianna Di Sario
,
Dalila Tarquini
,
Luca Proto
,
Anna Severino
,
Daniela Pedicino
,
Giovanna Liuzzo
Heart failure with preserved ejection fraction (HFpEF) is a complex and heterogeneous clinical syndrome, and the prevalence is expected to increase in the coming years. This condition poses a burden to the global health care system as the number of patients affected by this condition is constantly increasing due to a rising average lifespan. The absence of validated drugs effective in reducing hospitalization rates and mortality may reflect the impossibility of applying a one size fits all approach as in HFrEF, heading for a personalized approach. Available evidence demonstrated the link between collagen quantity and quality alterations, and cardiac remodeling. In the context of fibrosis, collagen cross-linking is strictly involved, displaying two types of mechanisms: enzymatic and non-enzymatic. In the murine model, enzymatic inhibition of fibrosis-inducing protease-activated receptor-1 (PAR1) and transforming growth factor (TGF)-β signaling appeared to reduce cardiac fibrosis. On the other hand, in the case of non-enzymatic cross-linking, sodium glucose co-transporter type 2 inhibitors (SGLT2is), appeared to counteract the deposition of advanced glycation end-products (AGEs), which in turn contributed to ventricular remodeling.
  • HFpEF
  • coronary microvascular dysfunction
  • cardiac remodeling
  • collagen
  • SGLT2i
  • AGEs

1. Introduction

Heart failure with preserved ejection fraction (HFpEF) is a complex and heterogeneous clinical syndrome that results from heart structural and functional changes, which makes the heart able to adequately pump blood to peripheral districts only at the cost of elevated cardiac filling pressures. This syndrome is characterized by signs and symptoms of HF, such as dyspnea and fatigue, but with a normal left ventricular ejection fraction (LVEF) and, evidence of structural and/or functional cardiac abnormalities consistent with the presence of LV diastolic dysfunction and raised LV filling pressures, according to the latest European Society of Cardiology guidelines [1]. More often diagnosed in women than in men, HFpEF is defined as a “female pattern”, even though it may soon be overcome because of the increasing diagnoses in men [2]. Due to its heterogeneous etiology, HFpEF embraces different phenotypes, sometimes showing a more fibrotic biological profile, while, on other occasions, displaying a more marked inflammatory identity [3]. This condition represents a burden on the health care system worldwide as the number of HFpEF patients is steadily increasing—firstly, due to a rise in the average life expectancy, and secondly, thanks to an easier clinical recognition—remaining one of the most challenging hot topics in the cardiovascular field. Indeed, because of its nature, the scientific community still lacks a perfect experimental animal model that mimics this complex condition, making drug development harder.

2. Endothelial Dysfunction and the HFpEF Microvascular Paradigm

Endothelial dysfunction plays a pivotal role in the pathophysiology of HFpEF [4]. Cardiovascular comorbidities, such as hypertension, atrial fibrillation, coronary artery disease, dyslipidemia, diabetes mellitus, obesity and obstructive sleep apnea, trigger a low-grade systemic pro-inflammatory state that leads to coronary microvascular dysfunction (CMD) and affects the perivascular environment, causing fibrosis and remodeling of the heart.
The latest updates in biomarker selection highlight the enormous complexity of CMD molecular pathways [5]. Among non-cardiovascular comorbidities, obesity elicits a chronic, low-grade systemic inflammatory state in HFpEF patients, which contributes to CMD through adipokine release and β-adrenergic receptor activation. Furthermore, obesity could be an indirect goal to stimulate other comorbidities, such as insulin resistance [6]. Diabetes mellitus also fuels the systemic inflammatory milieu, contributing to endothelial impairment. As in patients presenting with myocardial infarction [7], the concomitant metabolic dysregulation is characterized by an increase in glucose uptake and related glucose transporter 1 (GLUT-1). In the murine model, this condition is also typical of adverse LV remodeling, cardiomyocyte hypertrophy, and eventually a failing heart [8]. Hyperglycemia induces the glycation of interstitial proteins and oxidative stress leads to the formation of advanced glycation end products (AGEs), responsible for the increased LV stiffness. The transition from glucose utilization to the fatty acids-dependent state, lipotoxicity, and impaired insulin signaling, all contribute to HF in the diabetic setting [9][10].

3. Fibrosis and Extracellular Matrix Derangement in the Onset of HFpEF Stiffness

Fibrosis derives from the interplay of modifications that affect the cellular and extracellular microenvironment. The main changes concern cardiomyocyte hypertrophy, alteration of the giant sarcomeric myoprotein titin [11]—a bidirectional spring whose phosphorylation state affects cardiomyocyte passive stiffness—and excessive deposition of extracellular matrix (ECM). ECM alteration shapes a scaffold between cardiomyocytes and cardiac vessels leading to an imbalance of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPS) [12]. Furthermore, the myocardial ECM not only provides a mere mechanical support that preserves the geometry of the heart but constitutes a dynamic entity, whose turnover relies on fibroblasts which, in a pathological milieu, undergo a conversion towards collagen-producing myofibroblasts.
MMPs are in a latent state and their activation can be induced by ROS generation, leading to the degradation of ECM components. MMP1, MMP8 and MMP13 have a high affinity for collagen, while other MMPs have tropism for elastin and proteoglycans [13]. Mainly elastin, but also laminin, glycoproteins, and various collagen types, were reported as sources of ECM matrikines. Matrikines, ECM-derived peptides, may regulate ECM synthesis and remodeling and MMP generation and activation [14]. Furthermore, the impaired removal of these fragments is involved in the activation of the immune-mediated response, fueling ECM degradation, and further contributing to the disruption of myocardial integrity [15]. Selective enzymes, such as MMP-2, MMP-7, TIMP-1 and TIMP-2 increase with age, while MMP-9 shows the opposite trend. Both MMP and TIMP protein levels are augmented and seem to be associated with diastolic impairment in aged and healthy individuals, although more studies are required to further clarify their role in age-related ECM modifications [16][17]. In this general scenario, cardiomyocyte stiffening and interstitial fibrosis, deriving from collagen deposition and degradation imbalance, lead to LV diastolic dysfunction, the major impairment in HFpEF patients.

4. Qualitative and Quantitative Changes of Cardiac Collagen Fibers

Collagen is a vital, life-long and highly prevalent structural protein in mammals. The collagen family embraces 28 members, each consisting of 3 polypeptide subunits that assemble into a triple-helix structure domain [18]. Fibrillary collagen type I and III are the prevailing components of the ECM, accounting for nearly 80% and 10% of collagen in the healthy heart, respectively [19]. Under physiological conditions, triple helices generate microfibrils which, once assembled together, form larger fibers, increasing tissue stability [18]. Previous studies have shown a significant sex-related alteration in collagen metabolism, especially during the menopausal and postmenopausal phases, confirming the female HFpEF pattern and period [20]. Indeed, with aging, the collagen properties change, damaging its biochemical and biomechanical characteristics [21], thus leading to the loss of flexibility and altered enzymatic digestibility [22]. Age-related alterations in collagen strands play a central role in tissue stiffening. Several studies have proven, over the years, the reduction of the collagen fiber number in elderly people [23][24]. Furthermore, elderly adult collagen net is defined by fewer, longer, and thicker fibrils than the young-adult counterpart [23], highlighting the relevance of collagen quantity and quality. Quality features, such as collagen isoforms, collagen cross-linking (CCL) degree, and collagen type I to type III ratio and solubility, also play a role in diastolic impairment [12]. In HF related to pressure overload, the ratio of collagen type I to type III is increased [25] and is due to the augmented expression of type I collagen, which leads to an imbalance between myocardial stiffness and elasticity, properties respectively provided by the collagen isoform I and isoform III. Nevertheless, in ischemic cardiomyopathy -main cause of HFrEF-, the same index appears reduced, attributable to an increased expression of type III collagen. In this perspective, the collagen type ratio together with different collagen isoforms could be exploited as intriguing tools to distinguish between the two HF phenotypes [26] and to tailor therapeutic treatment. For instance, Graziani et al. hypothesized parallelism, transposing therapeutic strategies from idiopathic pulmonary fibrosis to HFpEF, targeting collagen production, induced by transforming growth factor-beta (TGF-β) signaling pathway, adopting nintedanib and pirfenidone [27]; thus, updating the possible new applications of these pharmacological treatments (Figure 1).
Figure 1. Collagen deposition and collagen cross-link (CCL) have a great influence on left ventricular (LV) stiffness in patients with heart failure (HF). CCL is the formation of intramolecular and intermolecular covalent bonds between lysine residues in collagen molecules, which greatly increases the tensile strength and stiffness of collagen fibers and makes them more resistant to degradation. Multiple pathways have been targeted by therapeutic pharmacological treatments to overcome myofibroblast production, such as nintedanib, pirfenidone, Xa and Iia inhibitors, while vorapaxar attempts to inhibit excessive collagen deposition. Finally, simtuzumab inhibits the lysyl oxidase 2 (LOX2) pathway, thus reducing collagen cross-link generation.

5. Myocardial Collagen Cross-Linking and Therapeutic Involvement in the Pharmacological Treatment of HFpEF

Collagen deposition and CCL are processes that make collagen fibers more resistant to degradation and fibrosis less reversible, through the formation of intramolecular and intermolecular bonds. In particular, CCL takes place through two different mechanisms: on the one hand, through an enzymatic pathway, catalyzed by a lysyl oxidase (LOX), a copper-dependent enzyme, which acts with high affinity on lysine or hydroxylysine residues and contributes to the formation of cross-link precursor allysine aldehydes [28]. On the other hand, CCL can occur through a non-enzymatic path, via a glycation process that includes the formation and accumulation of AGEs [29]. In a physiological milieu, the time frame of these two mechanisms seems to differ: the enzymatic CCL takes place preferentially in the early stages of collagen maturation, providing for the stabilization of the collagen fibrils; while the non-enzymatic one is attributable to aging, privileging the most advanced decades [30].
LOX, also known as LOX1, is the progenitor of a family of enzymes responsible for collagen and elastin cross-linking, which encompasses four other members, known as LOX-like proteins (LOXL1, LOXL2, LOXL3 and LOXL4). LOX1 shares with the progenitor the secretion as a precursor form that needs to be activated through proteolysis, while the other three members of the family do not require activation, paving the way for the hypothesis that LOX1 and LOXL1 could belong to a common subfamily [31]. Evidence proved an increase in myocardial LOX expression in HFpEF patients compared to controls [32]. Furthermore, Krasner et al. observed an interesting direct correlation between myocardial LOX expression, the degree of CCL and the echocardiographic diagnostic parameter E/e’ ratio [33]. This study might have corroborated the presence of a link between increased ventricular stiffness and collagen expression in the myocardial tissue of HFpEF patients. LOX is not the only player, but LOXL proteins also affect CCL, contributing to impaired cardiac function. Myocardial LOXL2 appears enhanced in HFpEF patients, displaying a direct correlation with the degree of CCL and with the E/e’ ratio [34]. In light of this background, both LOX and LOXL2 could represent intriguing targets to investigate to implement the exiguous pharmacological armamentarium of HFpEF pharmacology. The inhibition of LOXL2 through the administration of a selective human monoclonal antibody, known as simtuzumab, has already been investigated in clinical trials involving patients with idiopathic pulmonary fibrosis and liver fibrosis (Figure 1) [35]. Although no clinical trials exploring the role of simtuzumab in HF are available, it has been demonstrated that antibody-mediated inhibition or genetic disruption of Loxl2 greatly reduces stress-induced cardiac fibrosis and chamber dilatation, improving systolic and diastolic functions [34]. These results pave the way for future studies in HFpEF.

This entry is adapted from the peer-reviewed paper 10.3390/jcm12185862

References

  1. McDonagh, T.A.; Metra, M.; Adamo, M.; Gardner, R.S.; Baumbach, A.; Böhm, M.; Burri, H.; Butler, J.; Čelutkienė, J.; Chioncel, O.; et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2021, 42, 3599–3726.
  2. Nelson, M.D.; Wei, J.; Bairey Merz, C.N. Coronary microvascular dysfunction and heart failure with preserved ejection fraction as female-pattern cardiovascular disease: The chicken or the egg? Eur. Heart J. 2018, 39, 850–852.
  3. Lewis, G.A.; Schelbert, E.B.; Williams, S.G.; Cunnington, C.; Ahmed, F.; McDonagh, T.A.; Miller, C.A. Biological Phenotypes of Heart Failure with Preserved Ejection Fraction. J. Am. Coll. Cardiol. 2017, 70, 2186–2200.
  4. Mohammed, S.F.; Hussain, S.; Mirzoyev, S.A.; Edwards, W.D.; Maleszewski, J.J.; Redfield, M.M. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 2015, 131, 550–559.
  5. Rocco, E.; Grimaldi, M.C.; Maino, A.; Cappannoli, L.; Pedicino, D.; Liuzzo, G.; Biasucci, L.M. Advances and Challenges in Biomarkers Use for Coronary Microvascular Dysfunction: From Bench to Clinical Practice. J. Clin. Med. 2022, 11, 2055.
  6. Schiattarella, G.G.; Rodolico, D.; Hill, J.A. Metabolic inflammation in heart failure with preserved ejection fraction. Cardiovasc. Res. 2021, 117, 423–434.
  7. Canonico, F.; Pedicino, D.; Severino, A.; Vinci, R.; Flego, D.; Pisano, E.; d’Aiello, A.; Ciampi, P.; Ponzo, M.; Bonanni, A.; et al. GLUT-1/PKM2 loop dysregulation in patients with non-ST-segment elevation myocardial infarction promotes metainflammation. Cardiovasc. Res. 2022, 2022, cvac184.
  8. Rosenblatt-Velin, N.; Montessuit, C.; Papageorgiou, I.; Terrand, J.; Lerch, R. Postinfarction heart failure in rats is associated with upregulation of GLUT-1 and downregulation of genes of fatty acid metabolism. Cardiovasc. Res. 2001, 52, 407–416.
  9. Lopaschuk, G.D.; Karwi, Q.G.; Tian, R.; Wende, A.R.; Abel, E.D. Cardiac Energy Metabolism in Heart Failure. Circ. Res. 2021, 128, 1487–1513.
  10. Kenny, H.C.; Abel, E.D. Heart Failure in Type 2 Diabetes Mellitus. Circ. Res. 2019, 124, 121–141.
  11. Zile, M.R.; Baicu, C.F.; Ikonomidis, J.S.; Stroud, R.E.; Nietert, P.J.; Bradshaw, A.D.; Slater, R.; Palmer, B.M.; Van Buren, P.; Meyer, M.; et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: Contributions of collagen and titin. Circulation 2015, 131, 1247–1259.
  12. Fan, D.; Takawale, A.; Lee, J.; Kassiri, Z. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenes. Tissue Repair 2012, 5, 15.
  13. Horn, M.A.; Trafford, A.W. Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling. J. Mol. Cell. Cardiol. 2016, 93, 175–185.
  14. Mohindra, R.; Agrawal, D.K.; Thankam, F.G. Altered Vascular Extracellular Matrix in the Pathogenesis of Atherosclerosis. J. Cardiovasc. Transl. Res. 2021, 14, 647–660.
  15. Pedicino, D.; Giglio, A.F.; Ruggio, A.; Massaro, G.; D’Aiello, A.; Trotta, F.; Lucci, C.; Graziani, F.; Biasucci, L.M.; Crea, F.; et al. Inflammasome, T Lymphocytes and Innate-Adaptive Immunity Crosstalk: Role in Cardiovascular Disease and Therapeutic Perspectives. Thromb. Haemost. 2018, 118, 1352–1369.
  16. Lindsey, M.L.; Goshorn, D.K.; Squires, C.E.; Escobar, G.P.; Hendrick, J.W.; Mingoia, J.T.; Sweterlitsch, S.E.; Spinale, F.G. Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function. Cardiovasc. Res. 2005, 66, 410–419.
  17. Bonnema, D.D.; Webb, C.S.; Pennington, W.R.; Stroud, R.E.; Leonardi, A.E.; Clark, L.L.; McClure, C.D.; Finklea, L.; Spinale, F.G.; Zile, M.R. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J. Card. Fail. 2007, 13, 530–540.
  18. Ricard-Blum, S. The collagen family. Cold Spring Harb. Perspect. Biol. 2011, 3, a004978.
  19. Wilson, S.L.; Guilbert, M.; Sulé-Suso, J.; Torbet, J.; Jeannesson, P.; Sockalingum, G.D.; Yang, Y. A microscopic and macroscopic study of aging collagen on its molecular structure, mechanical properties, and cellular response. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2014, 28, 14–25.
  20. Dworatzek, E.; Mahmoodzadeh, S.; Schriever, C.; Kusumoto, K.; Kramer, L.; Santos, G.; Fliegner, D.; Leung, Y.K.; Ho, S.M.; Zimmermann, W.H.; et al. Sex-specific regulation of collagen I and III expression by 17β-Estradiol in cardiac fibroblasts: Role of estrogen receptors. Cardiovasc. Res. 2019, 115, 315–327.
  21. Schulze, C.; Wetzel, F.; Kueper, T.; Malsen, A.; Muhr, G.; Jaspers, S.; Blatt, T.; Wittern, K.P.; Wenck, H.; Käs, J.A. Stiffening of human skin fibroblasts with age. Biophys. J. 2010, 99, 2434–2442.
  22. Mikulíková, K.; Eckhardt, A.; Pataridis, S.; Miksík, I. Study of posttranslational non-enzymatic modifications of collagen using capillary electrophoresis/mass spectrometry and high performance liquid chromatography/mass spectrometry. J. Chromatogr. A 2007, 1155, 125–133.
  23. Guilbert, M.; Roig, B.; Terryn, C.; Garnotel, R.; Jeannesson, P.; Sockalingum, G.D.; Manfait, M.; Perraut, F.; Dinten, J.M.; Koenig, A.; et al. Highlighting the impact of aging on type I collagen: Label-free investigation using confocal reflectance microscopy and diffuse reflectance spectroscopy in 3D matrix model. Oncotarget 2016, 7, 8546–8555.
  24. Lovell, C.R.; Smolenski, K.A.; Duance, V.C.; Light, N.D.; Young, S.; Dyson, M. Type I and III collagen content and fibre distribution in normal human skin during ageing. Br. J. Dermatol. 1987, 117, 419–428.
  25. Echegaray, K.; Andreu, I.; Lazkano, A.; Villanueva, I.; Sáenz, A.; Elizalde, M.R.; Echeverría, T.; López, B.; Garro, A.; González, A.; et al. Role of Myocardial Collagen in Severe Aortic Stenosis With Preserved Ejection Fraction and Symptoms of Heart Failure. Rev. Esp. Cardiol. 2017, 70, 832–840.
  26. Collier, P.; Watson, C.J.; van Es, M.H.; Phelan, D.; McGorrian, C.; Tolan, M.; Ledwidge, M.T.; McDonald, K.M.; Baugh, J.A. Getting to the heart of cardiac remodeling; how collagen subtypes may contribute to phenotype. J. Mol. Cell. Cardiol. 2012, 52, 148–153.
  27. Graziani, F.; Varone, F.; Crea, F.; Richeldi, L. Treating heart failure with preserved ejection fraction: Learning from pulmonary fibrosis. Eur. J. Heart Fail. 2018, 20, 1385–1391.
  28. López, B.; González, A.; Hermida, N.; Valencia, F.; de Teresa, E.; Díez, J. Role of lysyl oxidase in myocardial fibrosis: From basic science to clinical aspects. Am. J. Physiol. Heart Circ. Physiol. 2010, 299, H1–H9.
  29. Paulus, W.J.; Zile, M.R. From Systemic Inflammation to Myocardial Fibrosis: The Heart Failure with Preserved Ejection Fraction Paradigm Revisited. Circ. Res. 2021, 128, 1451–1467.
  30. Marcos-Garcés, V.; Molina Aguilar, P.; Bea Serrano, C.; García Bustos, V.; Benavent Seguí, J.; Ferrández Izquierdo, A.; Ruiz-Saurí, A. Age-related dermal collagen changes during development, maturation and ageing—A morphometric and comparative study. J. Anat. 2014, 225, 98–108.
  31. Molnar, J.; Fong, K.S.; He, Q.P.; Hayashi, K.; Kim, Y.; Fong, S.F.; Fogelgren, B.; Szauter, K.M.; Mink, M.; Csiszar, K. Structural and functional diversity of lysyl oxidase and the LOX-like proteins. Biochim. Biophys. Acta 2003, 1647, 220–224.
  32. Rodríguez, C.; Martínez-González, J. The Role of Lysyl Oxidase Enzymes in Cardiac Function and Remodeling. Cells 2019, 8, 1483.
  33. Kasner, M.; Westermann, D.; Lopez, B.; Gaub, R.; Escher, F.; Kühl, U.; Schultheiss, H.P.; Tschöpe, C. Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J. Am. Coll. Cardiol. 2011, 57, 977–985.
  34. Yang, J.; Savvatis, K.; Kang, J.S.; Fan, P.; Zhong, H.; Schwartz, K.; Barry, V.; Mikels-Vigdal, A.; Karpinski, S.; Kornyeyev, D.; et al. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nat. Commun. 2016, 7, 13710.
  35. Raghu, G.; Brown, K.K.; Collard, H.R.; Cottin, V.; Gibson, K.F.; Kaner, R.J.; Lederer, D.J.; Martinez, F.J.; Noble, P.W.; Song, J.W.; et al. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: A randomised, double-blind, controlled, phase 2 trial. Lancet. Respir. Med. 2017, 5, 22–32.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback